Iridex announces first patient enrollment in MicroPulse TLT study

Iridex Corporation announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse(R) Transscleral Laser Therapy using Iridex’ Cyclo G6 Laser and the MicroPulse P3 Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David Bruce, President and CEO of Iridex, shared: “The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward multicenter participation enabling a large-scale view and significant in-country impact of our MicroPulse technology.” The study, titled “MicroPulse Transscleral Laser Therapy: A Prospective UK Study,” is set to expand Iridex’s global clinical portfolio, through its commitment to funding essential components of the 3-year study and providing a custom-designed and secure database management system. Both Iridex and Imperial College Healthcare NHS Trust are dedicated to conducting this study in accordance with the strictest ethical and regulatory standards and look forward to welcoming additional sites to join the program.